此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand

2022年5月29日 更新者:Chayasin Mansanguan、Mahidol University

Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.

This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.

Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.

All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).

研究概览

详细说明

Data Collection Methods

  1. Participants' demographics will be collected at baseline using case record form.
  2. Laboratory tests include: at 3 clinical visits (Baseline, Day3, Day7 and Day 14 (optional if have cardiac manifestation) after 2nd dose of Pfizer COVID-19 vaccine) 2.1. Cardiac biomarker (Troponin-T, CK-MB) 2.2. Echocardiography 2.3. ECG (Electrocardiography)

After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.

研究类型

观察性的

注册 (实际的)

314

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • BAngkok、泰国、10400
        • Faculty of Tropical Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

13年 至 18年 (孩子、成人)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Student age 13-18 who received 1st dose of pfizer COVID-19 vaccine from

  1. Kong thabbok upatham changkol kho so tho bo school
  2. Wachirathamsatit school

描述

Inclusion Criteria:

  1. Age 13-18 years old
  2. Both males and females
  3. Received 1st dose Pfizer COVID-19 vaccine injection

Exclusion Criteria:

  1. Unable to obtain written informed consent from the participants or their legal representatives
  2. History of cardiomyopathy, tuberculous pericarditis, and constrictive pericarditis
  3. Severe allergic reaction to COVID-19 vaccine

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at baseline
大体时间:Day 0
cardiac manifestation defined as sinus tachycardia, hypertension at baseline
Day 0
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 3
大体时间:Day 3
cardiac manifestation defined as sinus tachycardia, hypertension at day 3
Day 3
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 7
大体时间:Day 7
cardiac manifestation defined as sinus tachycardia, hypertension at day 7
Day 7

次要结果测量

结果测量
措施说明
大体时间
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at baseline
大体时间:Day 0
frequency (%) of participant with myocarditis at baseline
Day 0
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 3
大体时间:Day 3
frequency (%) of participant with myocarditis at day 3
Day 3
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 7
大体时间:Day 7
frequency (%) of participant with myocarditis at day 7
Day 7
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at baseline
大体时间:Day 0
frequency (%) of participant with pericarditis at baseline
Day 0
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 3
大体时间:Day 3
frequency (%) of participant with pericarditis at day 3
Day 3
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 7
大体时间:Day 7
frequency (%) of participant with pericarditis at day 7
Day 7
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at baseline
大体时间:Day 0
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline
Day 0
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 3
大体时间:Day 3
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3
Day 3
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 7
大体时间:Day 7
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7
Day 7

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Chayasin Mansanguan, M.D.、Mahidol University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年11月3日

初级完成 (实际的)

2021年11月29日

研究完成 (实际的)

2022年3月15日

研究注册日期

首次提交

2022年3月17日

首先提交符合 QC 标准的

2022年3月17日

首次发布 (实际的)

2022年3月21日

研究记录更新

最后更新发布 (实际的)

2022年6月2日

上次提交的符合 QC 标准的更新

2022年5月29日

最后验证

2022年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Data or leftover specimens will be shared for future study ONLY subjects who consent allow using their specimens. Sharing will be done without specimen identification.

IPD 共享时间框架

2 years after publication

IPD 共享支持信息类型

  • 研究方案
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

2019冠状病毒病疫苗的临床试验

Diagnostic of ECG的临床试验

3
订阅